Drug Development Pipeline
RELiZORB® is a digestive enzyme cartridge that connects to enteral tube feeding systems. It is designed to mimic normal pancreatic function by helping to break down the fats in enteral tube feeding formula. By breaking down these fats before the formula is ingested, RELiZORB® may allow for delivery of increased absorbable calories and simplify the use of enzymes in overnight feedings.
RELiZORB® is FDA-approved for children as young as 2 years old who require supplemental nutrition.
In clinical trials, participants with pancreatic insufficiency who used RELiZORB® were better able to absorb fat during their enteral tube feedings.
This program is sponsored by Alcresta and was partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
In September 2023, The U.S. Food and Drug Administration (FDA) expanded the approval of RELiZORB® to children ages 2 to 5 years old who use a feeding tube.
RELiZORB® was first cleared by the FDA for adults in 2015 and then expanded in 2017 to children ages 5 and older.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More